NO20065084L - Interferon-alfa polypeptider og konjugater - Google Patents
Interferon-alfa polypeptider og konjugaterInfo
- Publication number
- NO20065084L NO20065084L NO20065084A NO20065084A NO20065084L NO 20065084 L NO20065084 L NO 20065084L NO 20065084 A NO20065084 A NO 20065084A NO 20065084 A NO20065084 A NO 20065084A NO 20065084 L NO20065084 L NO 20065084L
- Authority
- NO
- Norway
- Prior art keywords
- conjugates
- polypeptides
- nucleic acids
- interferon
- alpha polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57250404P | 2004-05-19 | 2004-05-19 | |
PCT/US2005/017471 WO2005113592A2 (fr) | 2004-05-19 | 2005-05-18 | Polypeptides et conjugues interferon-alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065084L true NO20065084L (no) | 2006-12-01 |
Family
ID=35428915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065084A NO20065084L (no) | 2004-05-19 | 2006-11-03 | Interferon-alfa polypeptider og konjugater |
Country Status (14)
Country | Link |
---|---|
US (9) | US7318918B2 (fr) |
EP (1) | EP1753779A2 (fr) |
JP (1) | JP2008507298A (fr) |
CN (1) | CN101115769A (fr) |
AR (1) | AR049177A1 (fr) |
AU (1) | AU2005245918A1 (fr) |
BR (1) | BRPI0511196A (fr) |
CA (1) | CA2566247A1 (fr) |
IL (1) | IL178470A0 (fr) |
MX (1) | MXPA06013412A (fr) |
NO (1) | NO20065084L (fr) |
RU (1) | RU2006145020A (fr) |
TW (1) | TW200611910A (fr) |
WO (1) | WO2005113592A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1141275B1 (fr) | 1999-01-05 | 2009-08-12 | Trustees Of Boston University | Ligature perfectionnee d'acides nucleiques |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
US20030017552A1 (en) * | 2000-07-21 | 2003-01-23 | Jarrell Kevin A. | Modular vector systems |
US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
ES2585353T3 (es) * | 2004-05-12 | 2016-10-05 | Synchronoss Technologies, Inc. | Sistema de identificación de contactos avanzado |
JP2008519602A (ja) * | 2004-11-11 | 2008-06-12 | モジュラー ジェネティクス, インコーポレイテッド | 多様性を生じるためのラダーアセンブリおよびシステム |
JP5209462B2 (ja) * | 2005-03-09 | 2013-06-12 | ウェイ グアンウェン | コンセンサスインターフェロンの使用方法 |
BRPI0609809A2 (pt) * | 2005-05-18 | 2011-10-11 | Maxygen Inc | polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado |
AR078117A1 (es) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
WO2008008808A2 (fr) * | 2006-07-11 | 2008-01-17 | Modular Genetics Inc. | Procédés d'introduction d'une diversité ciblée dans des molécules d'acide nucléique |
US20100009908A1 (en) * | 2006-07-25 | 2010-01-14 | Nozomu Nishi | Galectin 9-Polymer Conjugates |
US7808342B2 (en) * | 2006-10-02 | 2010-10-05 | Skyworks Solutions, Inc. | Harmonic phase tuning filter for RF switches |
US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
WO2009006579A1 (fr) * | 2007-07-05 | 2009-01-08 | Pharmaessentia Corp. | Conjugués peptide-polymère |
US8106160B2 (en) * | 2007-10-01 | 2012-01-31 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
WO2009090056A2 (fr) * | 2008-01-18 | 2009-07-23 | F. Hoffmann-La Roche Ag | Purification de polypeptides non glycosylés |
US7954022B2 (en) * | 2008-01-30 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Apparatus and method for controlling dynamic modification of a scan path |
MX2011005051A (es) * | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
WO2010087994A2 (fr) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Procédés de ligature et utilisations associées |
TWI565714B (zh) * | 2011-06-02 | 2017-01-11 | 韓美科學股份有限公司 | 非肽基聚合物-胰島素集合體及其製造方法 |
CA2840409A1 (fr) | 2011-06-28 | 2013-01-03 | Whitehead Institute For Biomedical Research | Utilisation de sortases pour installer des attaches de chimie click pour la ligature de proteine |
CN102358897B (zh) * | 2011-10-31 | 2013-02-13 | 北京三元基因工程有限公司 | 重组人寡腺苷酸合成酶-1的制备方法 |
WO2015168474A1 (fr) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Protéines de fusion pour le traitement du cancer et procédés associés |
DK3006045T3 (en) * | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
CN115400220A (zh) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
RU2650755C1 (ru) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
CA3165442A1 (fr) * | 2020-01-24 | 2021-07-29 | R. Blair McNeill | Procedes de purification |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
ES8302778A1 (es) | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
JPS60152058A (ja) * | 1984-01-20 | 1985-08-10 | Toshiba Corp | 半導体記憶装置 |
ATE78262T1 (de) | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
US4695626A (en) * | 1986-07-29 | 1987-09-22 | Pfizer Inc. | 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
CA2094275C (fr) | 1990-10-17 | 2003-06-03 | Lawrence M. Blatt | Methodes et compositions pour le traitement de maladies cytoproliferatives |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
EP0741577B1 (fr) | 1994-03-07 | 2002-11-06 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE | Utilisation de sous-type 8 d'interferon alpha dans la preparation de medicaments permettant de traiter des infections virales du foie |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
CA2296770A1 (fr) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derives d'hormone de croissance et proteines associees |
IL144259A0 (en) | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
WO2000052153A2 (fr) * | 1999-03-02 | 2000-09-08 | Maxygen, Inc. | Ligands delegues pour recepteur orphelins |
BR0010725A (pt) | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
CA2385045A1 (fr) | 1999-10-07 | 2001-04-12 | Maxygen, Inc. | Homologues d'interferons alpha |
US20040002474A1 (en) | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
EP1231943A1 (fr) * | 1999-11-12 | 2002-08-21 | Maxygen Holdings Ltd | Conjugues d'interferon gamma |
DE60129432T2 (de) | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
AU2002223350A1 (en) | 2000-12-01 | 2002-06-11 | Eleanor N. Fish | Cytokine receptor binding peptides |
KR100459105B1 (ko) | 2001-02-15 | 2004-12-03 | 선바이오(주) | 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체 |
CN1323722C (zh) | 2002-11-15 | 2007-07-04 | 霍夫曼-拉罗奇有限公司 | PEG干扰素α-2a的位置异构体 |
KR20050086498A (ko) | 2002-11-18 | 2005-08-30 | 맥시겐, 인크. | 인터페론-알파 폴리펩티드 및 접합체 |
-
2005
- 2005-05-18 TW TW094116107A patent/TW200611910A/zh unknown
- 2005-05-18 CN CNA2005800241473A patent/CN101115769A/zh active Pending
- 2005-05-18 CA CA002566247A patent/CA2566247A1/fr not_active Abandoned
- 2005-05-18 EP EP05751765A patent/EP1753779A2/fr not_active Withdrawn
- 2005-05-18 WO PCT/US2005/017471 patent/WO2005113592A2/fr active Application Filing
- 2005-05-18 MX MXPA06013412A patent/MXPA06013412A/es unknown
- 2005-05-18 BR BRPI0511196-0A patent/BRPI0511196A/pt not_active Application Discontinuation
- 2005-05-18 US US11/132,722 patent/US7318918B2/en not_active Expired - Fee Related
- 2005-05-18 RU RU2006145020/04A patent/RU2006145020A/ru unknown
- 2005-05-18 AU AU2005245918A patent/AU2005245918A1/en not_active Abandoned
- 2005-05-18 JP JP2007527427A patent/JP2008507298A/ja active Pending
- 2005-05-19 AR ARP050102059A patent/AR049177A1/es unknown
-
2006
- 2006-09-13 US US11/531,557 patent/US7531324B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,531 patent/US7531630B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,570 patent/US20070020734A1/en not_active Abandoned
- 2006-09-14 US US11/532,024 patent/US20070225204A1/en not_active Abandoned
- 2006-09-14 US US11/532,045 patent/US20070225205A1/en not_active Abandoned
- 2006-10-05 IL IL178470A patent/IL178470A0/en unknown
- 2006-11-03 NO NO20065084A patent/NO20065084L/no unknown
-
2007
- 2007-05-04 US US11/744,424 patent/US7541436B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,730 patent/US7541163B2/en not_active Expired - Fee Related
- 2007-08-15 US US11/839,493 patent/US7537755B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008507298A (ja) | 2008-03-13 |
CA2566247A1 (fr) | 2005-12-01 |
US20070025966A1 (en) | 2007-02-01 |
CN101115769A (zh) | 2008-01-30 |
WO2005113592A3 (fr) | 2006-04-06 |
US7318918B2 (en) | 2008-01-15 |
MXPA06013412A (es) | 2007-01-23 |
BRPI0511196A (pt) | 2007-12-04 |
IL178470A0 (en) | 2007-02-11 |
AR049177A1 (es) | 2006-07-05 |
WO2005113592A2 (fr) | 2005-12-01 |
US7537755B2 (en) | 2009-05-26 |
US20070020235A1 (en) | 2007-01-25 |
US20080076710A1 (en) | 2008-03-27 |
US7531324B2 (en) | 2009-05-12 |
EP1753779A2 (fr) | 2007-02-21 |
AU2005245918A1 (en) | 2005-12-01 |
TW200611910A (en) | 2006-04-16 |
US7541163B2 (en) | 2009-06-02 |
US20080171363A1 (en) | 2008-07-17 |
RU2006145020A (ru) | 2008-06-27 |
US20070225204A1 (en) | 2007-09-27 |
US20080031853A1 (en) | 2008-02-07 |
US20070020734A1 (en) | 2007-01-25 |
US20070225205A1 (en) | 2007-09-27 |
US7531630B2 (en) | 2009-05-12 |
US7541436B2 (en) | 2009-06-02 |
US20050266465A1 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065084L (no) | Interferon-alfa polypeptider og konjugater | |
NO20052363L (no) | Interferon-alfa polypeptider og konjugater | |
WO2006083276A3 (fr) | Polypeptides et conjugues interferon-alpha | |
WO2004029219A3 (fr) | Interference arn basee sur les cellules, et procedes et compositions s'y rapportant | |
WO2005121331A8 (fr) | Polypeptides galnact2 tronques et acides nucleiques | |
HK1210627A1 (en) | Preparing crude biological estracts using protease, suitable for preparing cdna cdna | |
WO2003104418A3 (fr) | Polypeptides reconstitues | |
DK1409459T3 (da) | ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme. | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
NO20043564L (no) | Follistatindomene som inneholder proteiner | |
WO2004078120A3 (fr) | Compositions et biomateriaux de collagene | |
WO2006017538A3 (fr) | Proteines de liaison a la proteine hk1 | |
DK1641910T3 (da) | Glucanaser, nucleinsyrer, som koder for disse, og fremgangsmåder til at fremstille og benytte disse | |
DK1516053T3 (da) | Xylanaser, nucleinsyrer, som koder herfor, og fremgangsmåder til at fremstille og benytte disse | |
WO2006066024A3 (fr) | Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes | |
DK1131444T3 (da) | Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
WO2008121324A3 (fr) | Eléments de vecteurs d'expression recombinants (reve) destinés à augmenter l'expression de protéines recombinantes dans des cellules hôtes | |
WO2005087793A3 (fr) | Compositions immunostimulatrices et leurs utilisations | |
WO2004061080A3 (fr) | Polypeptides lies au stress et utilisation desdits polypeptides | |
WO2005103229A3 (fr) | Mitochondries trasngeniques, cellules et organismes transmitochondriaux et procedes de production associes | |
WO2004007664A3 (fr) | Vecteurs d'acides nucleiques | |
WO2006039396A3 (fr) | Technologie de microreseau tissulaire non enrobe pour analyses de proteines et d'acides nucleiques | |
WO2006063028A3 (fr) | Compositions immunostimulantes et utilisations de celles-ci |